

Amendment Statement of Principles

concerning

HYPOPITUITARISM  
(Reasonable Hypothesis)

(No. 53 of 2022)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 29 April 2022

|  |
| --- |
| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of: |
| Professor Terence Campbell AM  Chairperson |

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Amendment 3

1. Name

This is the Amendment Statement of Principles concerning *hypopituitarism* *(Reasonable Hypothesis)* (No. 53 of 2022).

1. Commencement

This instrument commences on 30 May 2022.

1. Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

1. Amendment

The Statement of Principles concerning *hypopituitarism* *(Reasonable Hypothesis)* (No. 11 of 2019) (Federal Register of Legislation No. F2019L00009) is amended in the following manner:

|  |  |
| --- | --- |
| **Section** | **Amendment** |
| *9(16)* | *Replace the existing factor in subsection 9(16) with the following*:  taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of hypopituitarism;  Note: ***immune checkpoint inhibitor*** is defined in the Schedule 1 - Dictionary. |
| *9(34)* | *Replace the existing factor in subsection 9(34) with the following*:  taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of hypopituitarism;  Note: ***immune checkpoint inhibitor*** is defined in the Schedule 1 - Dictionary. |
| *Schedule 1 – Dictionary* | *Replace the existing definition of "immune checkpoint inhibitor" with the following:*  ***immune checkpoint inhibitor*** means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab. |